PUBLISHER: The Business Research Company | PRODUCT CODE: 2111271
PUBLISHER: The Business Research Company | PRODUCT CODE: 2111271
Artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms are software-enabled systems that utilize machine learning, natural language processing, and data analytics to identify, evaluate, monitor, and prevent adverse drug reactions and other pharmaceutical safety concerns. These platforms analyze extensive clinical, real-world, and regulatory datasets to enhance signal detection, automate safety reporting, and ensure regulatory compliance throughout the entire drug development and commercialization lifecycle.
The primary components of artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms include software platforms and services. Software platforms refer to AI-enabled solutions that automate the collection, analysis, monitoring, and reporting of adverse drug events to strengthen drug safety and ensure regulatory compliance. These platforms are deployed through cloud-based, on-premise, and hybrid models and are adopted by large enterprises and small and medium-sized enterprises. The various applications include case processing and management, signal detection and management, risk management and reporting, and regulatory compliance, and they are used by several end users such as pharmaceutical companies, biotechnology companies, contract research organizations, regulatory authorities, healthcare providers, and academic and research institutes.
Tariffs are influencing the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market by increasing the cost of imported cloud infrastructure, high-performance computing systems, and advanced data analytics tools required for large-scale safety monitoring. This is slowing the deployment of pharmacovigilance solutions, particularly in Asia-Pacific and Europe, where pharmaceutical data ecosystems rely heavily on global technology imports. Software platforms and regulatory compliance systems are most affected due to their dependency on cross-border data infrastructure and integration tools. However, tariffs are also encouraging localized healthcare data infrastructure development, regional cloud investments, and stronger domestic regulatory technology ecosystems, ultimately improving data sovereignty and compliance resilience.
The artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market size has grown exponentially in recent years. It will grow from $2.14 billion in 2025 to $2.59 billion in 2026 at a compound annual growth rate (CAGR) of 20.6%. The growth in the historic period can be attributed to rise in global adverse drug reaction reporting requirements, increasing digitization of clinical trial data, expansion of pharmacovigilance regulatory frameworks, growth in pharmaceutical research activity, adoption of electronic health records in healthcare systems.
The artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market size is expected to see exponential growth in the next few years. It will grow to $5.39 billion in 2030 at a compound annual growth rate (CAGR) of 20.2%. The growth in the forecast period can be attributed to integration of ai into drug safety surveillance systems, expansion of real-world evidence based pharmacovigilance, increasing regulatory demand for automated compliance reporting, growth in predictive safety analytics platforms, rising adoption of cloud-based drug safety monitoring systems. Major trends in the forecast period include AI-powered adverse event detection systems, natural language processing based safety signal extraction, predictive pharmacovigilance analytics platforms, real-time drug safety monitoring using real-world data, automated regulatory safety reporting systems.
The increasing volume of adverse event (AE) reports is expected to propel the growth of the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market going forward. Adverse event (AE) reports refer to documented cases of unintended and harmful reactions or outcomes experienced after the use of a medical product or drug. The volume of adverse event (AE) reports is increasing due to stricter regulatory requirements that require healthcare providers and pharmaceutical companies to report a broader range of safety issues more frequently and in greater detail. Artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms process adverse event (AE) reports by aggregating data from clinical systems, electronic health records, and real-world sources to detect and classify safety signals, automate case processing, and improve the speed and accuracy of regulatory decision-making. For instance, in February 2024, according to the Analysis of Adverse Drug Reactions 2023 Report by the Department of Health Abu Dhabi, a UAE-based regulatory body, a total of 1,522 adverse drug reaction reports were submitted to the pharmacovigilance program between January and December 2023, representing a 235% increase compared to the average annual number of reports recorded in previous years. Therefore, the increasing volume of adverse event (AE) reports is driving the growth of the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market.
Key companies operating in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market are focusing on developing innovative treatments, such as agentic AI-driven pharmacovigilance platforms, to enhance automated adverse event detection, regulatory compliance, and efficiency in drug safety monitoring by reducing manual case-processing workloads and improving signal detection accuracy. Agentic AI pharmacovigilance platforms are advanced software systems that use domain-trained machine learning models, natural language processing, and workflow orchestration to independently perform and coordinate safety tasks such as case intake, literature surveillance, signal detection, and aggregate reporting. For example, in May 2026, RxLogix Systems Inc., a US-based pharmacovigilance solutions company, launched the upgraded PVOne.AI platform, an AI-enabled pharmacovigilance system that integrates agentic AI capabilities to automate and orchestrate end-to-end drug safety workflows. The platform operates across case intake, adverse event monitoring, literature surveillance, signal detection, aggregate reporting, and risk management, leveraging contextual reasoning and domain-trained models to support regulatory-grade decision-making. It also includes human-in-the-loop controls to ensure compliance with FDA and global pharmacovigilance standards while significantly reducing manual effort in case processing by up to 80%, improving reviewer productivity by up to 75%, and enabling up to 50% touchless workflows by minimizing repetitive tasks and enhancing prioritization of safety signals in large-scale pharmaceutical datasets.
In October 2024, EVERSANA Inc., a US-based pharmaceutical manufacturing company specializing in providing comprehensive AI-driven platforms and solutions for drug safety and pharmacovigilance (PV), partnered with Oracle Corporation to enhance pharmacovigilance and drug safety capabilities. Through this partnership, EVERSANA Inc. entered into a strategic collaboration agreement with Oracle Corporation to implement Oracle Argus Cloud Service, enabling AI-powered automation, workflow optimization, and touchless processing to improve safety case management, regulatory compliance, and global patient support services across the life sciences industry. Oracle Corporation is a US-based technology company specializing in cloud infrastructure, enterprise software, and healthcare and life sciences solutions.
Major companies operating in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market are Microsoft Corporation; International Business Machines Corporation; Accenture plc; Oracle Corporation; Cognizant Technology Solutions Corporation; IQVIA Holdings Inc.; Wipro Limited; ICON Public Limited Company; Fortrea; Clarivate Plc; Genpact Limited; Veeva Systems Inc.; ArisGlobal; Certara Inc.; Tempus AI Inc.; Komodo Health Inc.; Elsevier B.V.; Navitas Life Sciences; PrimeVigilance; Ennov Group SAS; Cloudbyz Inc.; Phesi; Medrio Inc.; Genomics England Limited
North America was the largest region in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market includes revenues earned by entities by providing services such as software licensing and subscription, cloud-based pharmacovigilance solutions, adverse event detection and reporting systems, data integration and interoperability solutions, predictive safety analytics, regulatory compliance support, system customization and integration, maintenance and technical support, consulting, and training services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market statistics, including artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms industry global market size, regional shares, competitors with a artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market share, detailed artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms industry. This artificial intelligence (AI)-driven drug safety and pharmacovigilance platforms market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Artificial Intelligence (AI)-Driven Drug Safety And Pharmacovigilance Platforms Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses artificial intelligence (ai)-driven drug safety and pharmacovigilance platforms market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for artificial intelligence (ai)-driven drug safety and pharmacovigilance platforms ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The artificial intelligence (ai)-driven drug safety and pharmacovigilance platforms market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.